MDxHealth Prostate Cancer Test Gains New York State Approval
December 4, 2018The approval completes MDxHealth’s state licensing requirements for SelectMDx, allowing the firm to offer the liquid biopsy test in all 50 US states.
SelectMDx is a noninvasive urine-based molecular diagnostic assay to identify patients at increased risk of aggressive prostate cancer. The company hopes the test will help to reduce unnecessary MRI and biopsy procedures in men with signs of a possible prostate cancer.
Source: https://www.genomeweb.com/cancer/mdxhealth-prostate-cancer-test-gains-new-york-state-approval